Japan's Regenerative Cell Therapy Push Advances With Regulatory Review, Market Growth, and New Patents
Japan's health ministry panel is reviewing two regenerative cell therapies for Parkinson's disease and heart failure, testing the country's push to build a domestic cell-based treatment industry. Japan's cell culture market is projected to reach USD 2.34 billion by 2031, driven by government support and favorable regulatory pathways. Australian firm Cartherics secured a Japanese patent for its iPSC-based immune cell therapies.
A Japanese health ministry panel is set to review two regenerative therapies facing regulatory approval, marking a pivotal test of the country's long-running push to build a domestic industry around advanced cell-based treatments. The panel will assess therapies including a treatment for Parkinson's disease from Sumitomo Pharma Co. and a separate therapy for heart failure developed by Cuorips Inc., both based on technology discovered by a Japanese Nobel Prize laureate.
The regulatory review comes amid broader momentum in Japan's regenerative medicine sector. Japan's cell culture market is projected to reach USD 2.34 billion by 2031 from USD 1.28 billion in 2026, growing at a compound annual growth rate of 12.8%. The market is expanding steadily, driven by the rise in product launches and growing demand for regenerative medicine and cell-based therapies. Government support for biotechnology research, favorable regulatory pathways for cell therapy products, and rising investments in pharmaceutical and biopharmaceutical research are further accelerating demand for advanced cell culture systems and consumables.
Regulatory support from government authorities, particularly through accelerated approval pathways established under the Pharmaceutical and Medical Devices Act, is encouraging innovation and collaborative research efforts. Pharmaceutical and biotechnology companies accounted for 57.57% of the end-user share in 2025, with the biopharmaceutical production segment projected to register a growth rate of 13.9% during the forecast period. The sera, media, and reagent segment of consumables is also projected to register a growth rate of 13.9%. Thermo Fisher Scientific, Merck KGaA, and FUJIFILM Holdings were identified as leading players in the Japan cell culture market.
The favorable environment is drawing international interest as well. Australian cell therapy company Cartherics has announced that the Japanese Patent Office has issued a new patent for its off-the-shelf immune cell therapies. The grant, the second in Japan from this patent family, extends protection for key features of induced pluripotent stem cells that have been gene-edited to incorporate chimeric antigen receptor constructs for cancer and, potentially, endometriosis. The company described the Japanese patent as an important milestone in its global IP strategy, noting that Japan is a major market for regenerative medicine and advanced cell therapies, offering significant commercial and partnering opportunities.
Cartherics is focused on high-impact women's diseases with lead programs in ovarian cancer and endometriosis. Its allogeneic cell platform is based on iPSCs derived from donated cord blood that can be differentiated into NK cells, T cells, and other immune cells. The company's lead product, CTH 401, is a CAR iNK cell therapy targeting the tumour antigen TAG 72. Cartherics has initiated manufacturing of clinical trial material and plans to file an Investigational New Drug application in late 2026, with first human trials in ovarian cancer to follow.